AT 012
Alternative Names: APL-2302; ASN-3186; AT-012Latest Information Update: 15 Oct 2024
At a glance
- Originator Asieris Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action USP1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer; Ovarian cancer
Most Recent Events
- 28 Aug 2024 Asieris Pharmaceuticals announces intention of IND approval in 2024
- 29 Apr 2024 AT 012 is available for licensing as of 29 Apr 2024. https://asieris.com/partner/
- 05 Apr 2024 Pharmacodynamics data from the preclinical trials presented at the 115th Annual Meeting of the American Association for Cancer Research 2024 (AACR-2024)